Peptide vaccines for cancers expressing tumor-associated antigens

Abstract

The present invention provides such as SEQ ID NO: 19, 22, 30, 34, 344, 358, 41, 44, 46, 48, 78, 376, 379, 80, 100, 101, 110, 111, 387, 112, 394, 114, 116, 117, 121, 395, 133, 135, 137, 426, 174, 178, 186, 194, 196, 202, 210, 213, 214, 217, 223, 227, 228, 233, 254, Peptides having the amino acid sequence shown in 271, 272 or 288, and peptides having the above amino acid sequence in which 1, 2 or more (for example, up to 5) amino acids have been substituted, deleted or added, these peptides have cytotoxic T Cell induction ability. The present invention also provides a medicament for treating or preventing diseases (such as cancer) associated with the overexpression of CDH3, EPHA4, ECT2, HIG2, INHBB, KIF20A, KNTC2, TTK and / or URLC10, which contains one or more Such peptides serve as active ingredients. The peptides of the invention can also be used as vaccines.

Description

technical field [0001] This patent application claims the benefit of US Provisional Patent Application 60 / 902,949, filed February 21, 2007, which is hereby incorporated by reference in its entirety for all purposes. [0002] The present invention relates to the field of biological sciences, and more particularly, to the field of cancer treatment. In particular, the present invention relates to novel immunogenic peptides that are extremely effective as cancer vaccines, and to medicaments for treating and preventing tumors comprising these peptides. Background technique [0003] It has been demonstrated that CD8 + Cytotoxic T lymphocytes (CTLs) can recognize epitope peptides derived from tumor-associated antigens (TAA) presented on MHC-class I molecules, and subsequently lyse tumor cells. Since the discovery of the first TAA-MAGE family, many other TAAs have been discovered using immunological methods (Boon T. (1993) Int J Cancer 54: 177-80.; Boon T. et al., (1996) J Exp Me...

AI Technical Summary

Problems solved by technology

Moreover, the algorithm described, for example BIMAS (http: / / bimas.dcrt.nih.gov / cgi-bin / molbio / ken_parker_comboform) (Parker KC, et al., (1994) J Immunol.; 152(1): 163-75.; Kuzushima K, et al., (2001) Blood.; 98(6):1872-81.)), although it can suggest that HLA molecules bind peptides, the peptides suggested are not very strict (Bachinsky MM , et.al., Cancer Immun.2005 Mar 22; 5: 6.)

Therefore, there are still many challenges and difficulties in TAA screening

Images